Edesa Biotech, Inc. (EDSA) Stock: Why It’s Down


Edesa Biotech, Inc. (EDSA) is working its way for to the bottom in the market today. The stock, one that is focused on the biotechnology sector, is currently trading at $6.16 after a move down of -7.37% so far today. In terms of biotech stocks, there are several factors that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories centered around EDSA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-20-19 12:12PM Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval
08:26AM Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial
07:30AM Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
Jun-20-19 12:12PM Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval
08:26AM Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial

Nonetheless, when making a decision with regard to investing, investors should look at much more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s happing when it comes to Edesa Biotech, Inc..

Recent Movement From EDSA

While a move down on a single session, like the fall that we’re seeing from Edesa Biotech, Inc. might make some investors fearful, a single session decline by itself should not be the basis of a decision to, or not to, invest in a company. It is generally smart to dig into trends further out than a single trading session. In the case of EDSA, here are the returns on investment that investors have experienced:

  • Past 7 Days – In the past five trading sessions, EDSA has produced a price change in the amount of -12.75%.
  • Past Month – The monthly ROI from Edesa Biotech, Inc. comes to 57.14%.
  • Past Three Months – Over the last quarter, the stock has generated a return that works out to -4.94%
  • Past 6 Months – Throughout the last 6 months, investors have seen a change that works out to -8.33% from the company.
  • Year To Date – Since the close of last year EDSA has produced a ROI of 12.82%.
  • Full Year – Lastly, over the last full year, we’ve seen movement that comes to -42.32% out of EDSA. In this period, the stock has traded at a high price of -64.60% and a low of 71.59%.

Important Ratios

Digging into a few key ratios associated with a stock generally gives investors an understanding of just how dangerous and/or rewarding a pick might be. Below are some of the key ratios to consider when looking at EDSA.

Short Ratio – The short ratio is a tool that’s used by investors to measure the amount of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is headed for declines. Throughout the sector, biotech stocks can come with a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Edesa Biotech, Inc., it’s short ratio clocks in at 0.06.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to pay for its debts when they mature using quick assets or current assets. In the biotech industry, many companies are heavily reliant on continued investor support, these ratios can seem upsetting. Nonetheless, several good picks in the biotech sector do have great current and quick ratios. In terms of EDSA, the quick and current ratios add up to 9.00 and 9.20 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price. In this case, the book to share value ratio is 1.55.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. When it comes to EDSA, the cash to share value comes to 1.12.

What Analysts Say About Edesa Biotech, Inc.

Although it’s not a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to consider their thoughts when validating your own before making an investment decision in the biotechnology industry. Here are the recent moves that we have seen from analysts as it relates to EDSA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EDSA, here’s what we’re seeing:

  • Institutions – As it stands now, institutional investors own 1.30% of EDSA. However, it’s important to consider that the ownership held by institutions has changed in the amount of 4.70% throughout the last quarter.
  • Investors On The Inside – When it comes to insiders, members of the management team and others close to EDSA currently hold 1.30% of the company. Their ownership of the company has changed by 0 over the last quarter.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 6.85M shares of Edesa Biotech, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, EDSA has a float of 4.30M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to EDSA, the short percent of the float is 0.45%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.91. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, EDSA has generated revenue in the amount of $-17.20% with earnings coming in at 38.30%. On a quarter over quarter basis, earnings have seen movement of 65.50% and revenue has seen movement of 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m heavily dependent on human beings. After all, humans built me! While, my creators made it possible for me to learn by myself, it’s much simpler to learn with the help of feedback from humans. Below this content, you will see a comment section. If you would like for me find other information, change the way I communicate, look at something from a different perspective, or just about anything else, I want to know. If you’ve got something to offer consider leaving a comment below. I will process that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here